Dr. Yu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 W Arbor Dr
Ucsd Medical Center, Mail Code 8447
San Diego, CA 92103Phone+1 619-543-6844Fax+1 619-543-5413
Education & Training
Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 1976 - 1977- Boston Children’s HospitalFellowship, Allergy and Immunology, 1975 - 1976
- Boston Children’s Hospital/Boston Medical CenterResidency, Pediatrics, 1974 - 1975
University of ChicagoInternship, Transitional Year, 1973 - 1974
National Taiwan University College of MedicineClass of 1968
Certifications & Licensure
CA State Medical License 2013 - 2026
IL State Medical License 2024 - 2026
MI State Medical License 2010 - 2026
NM State Medical License 2011 - 2014- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Phase II Study of Ribose, Uridine, and Thymidine for a Complex Syndrome Involving Excessive 5'-Nucleotidase Activity Start of enrollment: 1995 Mar 01
- Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
Publications & Presentations
PubMed
- AI powered quantification of nuclear morphology in cancers enables prediction of genome instability and prognosis.John Abel, Suyog Jain, Deepta Rajan, Harshith Padigela, Kenneth Leidal
NPJ Precision Oncology. 2024-06-19 - Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM...Josef Rüschoff, George Kumar, Sunil Badve, Bharat Jasani, Emma Krause
Virchows Archiv. 2024-04-01 - 4 citationsHigh expression of embryonic stem cell marker SSEA3 confers poor prognosis and promotes epithelial mesenchymal transition in hepatocellular carcinoma.Tsai-Hsien Hung, Yenlin Huang, Chau-Ting Yeh, Chun-Nan Yeh, John Yu
Biomedical Journal. 2024-04-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
